

AMI KOTHARI, MD

9000 WAUKEGAN ROAD, MORTON GROVE, IL 60053
(847) 375 – 3000

EXPERIENCE

Illinois Bone and Joint Institute, LLC Rheumatologist	Morton Grove, IL September 2009 to Present
Rheumatology Director	January 2021 to Present
Lab Director Moderate/ High Complexity CLIA certified lab	January 2021 to Present

MEDICAL TRAINING

Northwestern University <i>Rheumatology Fellowship (3-year Program)</i>	Chicago, IL 2006 to 2009
University of Illinois at Chicago <i>Internship 2003</i> <i>Internal Medicine Residency 2004-2006</i>	Chicago, IL 2003 to 2006

EDUCATION

University of Illinois at Chicago <i>College of Medicine</i> <ul style="list-style-type: none">▪ Recipient of Doctor of Medicine in May, 2003	Chicago, IL 1999 to 2003
University of Illinois at Chicago <i>College of Liberal Arts and Sciences</i> <ul style="list-style-type: none">▪ Recipient of Bachelor of Science in Biological Sciences with Highest Honors in May, 1999▪ Minor in Chemistry▪ Honors College▪ Guaranteed Professional Program Admissions	Chicago, IL 1996 to 1999

LICENSES & CERTIFICATIONS

- Board Certified in Rheumatology
 - 10 year Re-certification completed/passed on 10/1/2020
- Board Certified in Internal Medicine in August, 2007
- ISCD certified
- Passed USMLE Step 3 in June, 2005
- Passed USMLE Step 2 in August, 2002
- Passed USMLE Step 1 in June, 2001

RESEARCH EXPERIENCE

Northwestern University <i>Department of Rheumatology</i> <ul style="list-style-type: none">▪ Clinical research with Dr. Leena Sharma in Osteoarthritis<ul style="list-style-type: none">○ Within-Region Analysis of the Relationship of Bone and Cartilage Lesions in Knee Osteoarthritis	Chicago, IL June 2007 to June 2009
Northwestern University <i>Department of Rheumatology</i> <ul style="list-style-type: none">▪ Clinical research with Dr. H.J. Chang	Chicago, IL September, 2004

AMI KOTHARI, MD

9000 WAUKEGAN ROAD, MORTON GROVE, IL 60053
(847) 375 – 3000

- Joint Replacement Surgery: Social Support, Ethnicity, and Gender Patterns in Decision Making

PRESENTATIONS

Northwestern University **Chicago, IL**
Department of Rheumatology October 18, 2007
Rheumatology Grand Rounds
Whipple's Disease: A Review

Northwestern University **Chicago, IL**
Department of Rheumatology March 01, 2007
Rheumatology Grand Rounds
Henoch-Schonlein Purpura: Clinical Case and Review

Northwestern University **Chicago, IL**
Department of Rheumatology April 28, 2008
MCRC Conference
The Sequence of Bone and Cartilage Lesions in Knee Osteoarthritis

Chicago Rheumatology Fellows Meeting **Chicago, IL**
Pneumococcal Septic Arthritis December 10, 2008

Northwestern Medicine Fellows Research Conference Series

Chicago, IL
The Within-Subregion Relationship between Bone Marrow Lesions and
Cartilage Loss in Knee Osteoarthritis January 20, 2009

COMMITTEES

Illinois Bone and Joint Institute **Morton Grove, IL**
Practice Management Committee Member-Morton Grove Division 2015 to 2020
Chair of the Risk Committee 2021 to present
Vice-Chair of the Risk Committee 2018 to 2020
Near North Operations Committee 2021 to present

ACADEMIC HONORS

- *Phi Eta Sigma* National Honor Society
- *Phi Kappa Phi* Honor Society
- Golden Key National Honors Society

PROFESSIONAL AFFILIATIONS

- American College of Rheumatology
 - International Society of Clinical Densitometry
-

AMI KOTHARI, MD

9000 WAUKEGAN ROAD, MORTON GROVE, IL 60053
(847) 375 – 3000

PUBLICATIONS

Abstracts:

- **Within-Region Analysis of the Relationship of Bone and Cartilage Lesions in Knee Osteoarthritis** Ami Kothari¹, September Cahue¹, Ali Guermazi², Jing Song¹, Dorothy Dunlop¹, Meredith Marshall¹, Leena Sharma¹. ¹Northwestern University, Chicago, IL; ²Boston University, Boston, MA
Presented 10/26/08 at the American College of Rheumatology Conference in San Francisco Poster Session

RESEARCH ACTIVITIES

Sub-Investigator:

- 999RA002: Biomarkers of Anti-TNF- α Therapy Efficiency in Rheumatoid Arthritis to Define Unresponsive Patients. Funded by Crescendo Bioscience. 2012 – Ongoing
- CAIN457F2309: A randomized, double-blind, placebo- and active-controlled study of secukinumab to demonstrate the efficacy at 24 weeks and to assess the safety, tolerability and long-term efficacy up to 1 year in patients with active rheumatoid arthritis who have an inadequate response to anti-TNF α agents. Funded by Novartis. 2011 – Ongoing
- H9B-MC-BCDP: A phase 3b, multicenter, open-label study to evaluate the long-term safety and efficacy of LY2127399 in patients with rheumatoid arthritis (RA). Funded by Eli Lilly. 2011 – Ongoing
- A3921129: A randomized, double-blind, placebo-controlled phase 2 study to assess the immune response following administration of influenza and pneumococcal vaccines to subjects with rheumatoid arthritis receiving CP-690,550 or placebo CP-690,550 with and without background methotrexate. Funded by Pfizer. 2011 – Ongoing
- 10-OA-004: An open-label, safety extension study of repeat dosing with intra-articular bone morphogenetic protein (BMP-7) in subjects with osteoarthritis (OA) of the knee. Funded by Stryker Biotech. 2011 – Ongoing
- H9B-MC-BCDO: A phase 3, multi-center, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of LY2127399 in patients with rheumatoid arthritis (RA) with or without background disease-modifying anti-rheumatic drug (DMARD) therapy. Funded by Eli Lilly. 2010 – Ongoing
- WA22762: A randomized, double-blind, parallel group study of the safety and effect on clinical outcome of tocilizumab SC versus tocilizumab IV, in combination with traditional disease modifying anti-rheumatoid arthritis drugs (DMARDs), in patients with moderate to severe active rheumatoid arthritis. Funded by Roche. 2010 – Ongoing
- 09-OA-002: A phase 2, double-blind, randomized, placebo-controlled, proof of concept, dose-finding study of intra-articular bone morphogenetic protein (BMP-7) in subjects with osteoarthritis (OA) of the knee. Funded by Stryker Biotech. 2010 – 2011
- WA19926: A multi-center, randomized, double-blind, parallel group study of the safety, remission and prevention of structural joint damage during treatment with Tocilizumab (CZ), as a monotherapy and in combination with methotrexate (MTX), versus methotrexate in patients with early, moderate to severe early rheumatoid arthritis (RA). Funded by Roche. 2009 – Ongoing
- HZ-CA-401: Open-label safety study of HZT-501 in patients who require long-term daily non-steroidal anti-inflammatory drug treatment. Funded by Horizon Therapeutics. 2009 – 2011
- A4091016: A phase 3, multi-center, randomized, long-term study of the safety of Tanezumab in patients with osteoarthritis of the knee or hip. Funded by Pfizer. 2009 – 2011
- F1J-MC-HMGP: Duloxetine 60 mg once daily versus placebo in the treatment of patients with osteoarthritis knee pain. Funded by Eli Lilly. 2009 – 2010
- ML 22533/B: An open-label, randomized study to evaluate the safety, tolerability and efficacy of tocilizumab (TCZ) monotherapy or TCZ in combination with non-biologic disease modifying anti-rheumatic drugs (DMARDs) in patients with active rheumatoid 2009 – 2011

AMI KOTHARI, MD

9000 WAUKEGAN ROAD, MORTON GROVE, IL 60053
(847) 375 – 3000

arthritis who have an inadequate response to current non-biologic or biologic DMARDs. Funded by Roche.

- C87084: A phase 3b, multi-center open-label, follow-up study to evaluate the safety and efficacy of certolizumab pegol administered concomitantly with methotrexate in patients with active rheumatoid arthritis who participated in C87077. Funded by UCB. 2009 – 2011

- A4091015: A phase 3 randomized, double-blind placebo and Naproxen-controlled multi-center study of the analgesic efficacy and safety of Tanezumab in patients with osteoarthritis of the knee. Funded by Pfizer. 2009 – 2010
- A3921044: A phase 3 randomized, double-blind, placebo-controlled study of the efficacy and safety of 2 doses of CP-690,550 in patients with active rheumatoid arthritis on background methotrexate. Funded by Pfizer. 2009 – Ongoing
- ACT 4562g: A phase 2, randomized, double-blind, parallel group study to evaluate the efficacy and safety of ocrelizumab in combination with methotrexate compared with Infliximab plus methotrexate in patients with active rheumatoid arthritis currently responding inadequately to Etanercept or Adalimumab. Funded by Genentech. 2009 – 2011
- C87077: Evaluation of the safety and efficacy of an Certolizumab Pegol-administered concomitantly with a stable-dose methotrexate in patients with active rheumatoid arthritis (RA). Funded by UCB. 2007 – 2011
- A3921024: A long-term, open-label follow-up study of Tasocitinib (CP-690,550) for treatment of rheumatoid arthritis. Funded by Pfizer. 2007 – Ongoing
- WA20495/ACT3986g: A randomized, double-blind, parallel group, international study to evaluate the safety and efficacy of ocrelizumab compared to placebo in patients with active rheumatoid arthritis who have an inadequate response to at least one anti-TNF therapy. Funded by Genentech. 2007 – 2011
- WA20494/ACT3985g: A randomized, double-blind, parallel group, international study to evaluate the safety and efficacy of ocrelizumab compared to placebo in patients with active rheumatoid arthritis continuing methotrexate treatment. Funded by Genentech. 2006 – 2011
- WA 18696: A long-term extension study of safety during treatment with tocilizumab (MRA) in patients completing treatment in MRA core studies. Funded by Hoffman-La Roche. 2006 – Ongoing